EUVIMEDEUVIMED entdecken
Crossref

Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy

Rui Li, Yuhao Hao, Wen Pan, Wei Wang, Yuanzeng Min

Acta Biomaterialia · 2023-11 · 171 · 482-494

DOI: 10.1016/j.actbio.2023.09.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2023-11. Verfasst von Rui Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Science and Technology of China, Hefei, 230026, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, University of Science and Technology of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic cancer nanovaccines can induce strong antitumor immunity and establish long-term immune memory and have shown potential for curing tumors in some clinical trials. However, weak immunogenicity and safety concerns of nanocarriers limit the clinical translation of some therapeutic nanovaccines. Here, we developed minimal-component cancer nanovaccines, monophosphoryl lipid A (MPLA)-assembled nanovaccines (MANs), that could facilitate the clinical application of nanovaccines. The MANs were formed by protein antigens extracted from chemotherapy-induced tumor cell cultures and the amphiphilic immune adjuvant MPLA. Compared with free chemotherapy-induced antigens, MANs can activate the Toll-like receptor 4 (TLR4)-mediated signalling pathway and promote adaptive immunity against tumor antigens. Mechanistic analysis indicated that MANs induced antigen capture of DCs and promoted the activation of DCs and T cells, thereby optimizing the ratio of CD8+ T/Tregs in tumors and facilitating the transformation of the tumor immune microenvironment (TIME) from "cold" to "hot". In a CT26 colorectal cancer model, MANs+αPD-1 significantly improved the efficacy of αPD-1 treatment. Our work offers a strategy for designing minimal-component cancer nanovaccines with potential clinical benefits. STATEMENT OF SIGNIFICANCE: To address the weak immunogenicity of cancer vaccines and the safety concerns of nanocarriers, we prepared MPLA-assembled nanovaccines (MANs) using chemotherapy induced antigens and the immune adjuvant MPLA to promote cancer vaccines to clinical practice. MANs effectively internalized tumor antigens and induced DC maturation, indicating that the initial anti-tumor response had been activated. MANs+αPD-1 induced APCs, CD8+ T cells and memory T cells with positive anti-tumor effects to migrate to tumor tissue, thus leading to the transformation of the tumor immune microenvironment from "cold" to "hot". At the animal level, the combination of MANs and αPD-1 exerted synergistic effects and significantly enhanced tumor immunotherapy. Therefore, the treatment regimen of MANs+αPD-1 has potential clinical benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsAntineoplastic AgentsAnimalsHumansCD8-Positive T-LymphocytesImmunotherapyAdjuvants, ImmunologicAntigens, NeoplasmTumor MicroenvironmentLipid A

Stichwörter der Autor:innen

Chemotherapy-induced antigensImmune checkpoint blockersTherapeutic nanovaccinesToll-like receptor 4 agonistsTumor immune microenvironment

Substanzen

Cancer VaccinesAdjuvants, ImmunologicAntigens, NeoplasmAntineoplastic Agentsmonophosphoryl lipid ALipid A

Autor:innen und Institutionen

  • Department of Chemistry, University of Science and Technology of China, Hefei, 230026, China.
  • Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Electronic address: docweiwang@ustc.edu.…
  • Department of Chemistry, University of Science and Technology of China, Hefei, 230026, China; Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, University of Scien…

Förderung

  • National Natural Science Foundation of China
  • University of Science and Technology of China
  • Fundamental Research Funds for the Central Universities
  • Natural Science Foundation of Anhui Province

Zitieren

APA

Li, R., Hao, Y., Pan, W., Wang, W., & Min, Y. (2023). Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy. Acta Biomaterialia, 171, 482-494. https://doi.org/10.1016/j.actbio.2023.09.013

Vancouver

Li R, Hao Y, Pan W, Wang W, Min Y. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy. Acta Biomaterialia. 2023;171:482-494. doi:10.1016/j.actbio.2023.09.013

BibTeX
@article{Li2023,
  author = {Li, Rui and Hao, Yuhao and Pan, Wen and Wang, Wei and Min, Yuanzeng},
  title = {Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy},
  journal = {Acta Biomaterialia},
  year = {2023},
  volume = {171},
  pages = {482--494},
  doi = {10.1016/j.actbio.2023.09.013}
}
Kostenlos starten →